Stack library
Peptide stacks
11 combinations, each with the rationale for stacking, per-compound dosing, and worked reconstitution math for both separate vials and a single pre-blended vial.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Wolverine (BPC-157 + TB-500)
The 'Wolverine' stack pairs two of the most widely discussed repair peptides because their proposed mechanisms are complementary rather than redundant. BPC-157 is associated with angiogenesis and localized tendon/ligament/gut signaling, while TB-500 (a synthetic fragment of thymosin beta-4) is associated with actin regulation and cell migration across tissue.
GLOW (BPC-157 + TB-500 + GHK-Cu)
GLOW extends the Wolverine repair pairing with GHK-Cu, a copper-binding tripeptide associated with collagen synthesis, skin remodeling, and wound cosmesis. The idea is to combine systemic/structural repair (BPC-157 + TB-500) with a skin- and collagen-oriented signal (GHK-Cu).
KLOW (KPV + BPC-157 + TB-500 + GHK-Cu)
KLOW adds KPV — a tripeptide fragment of alpha-MSH with anti-inflammatory properties — to the GLOW stack, aiming to pair tissue/skin repair with an inflammation- and gut-oriented signal.
CJC-1295 (no-DAC) + Ipamorelin
This is the classic growth-hormone-secretagogue pairing. CJC-1295 without DAC (a GHRH analog, also called Mod GRF 1-29) increases the amount of GH released per pulse, while Ipamorelin (a selective ghrelin-receptor agonist) triggers a clean GH pulse with minimal effect on cortisol or prolactin.
CagriSema (Cagrilintide + Semaglutide)
CagriSema combines a long-acting amylin analog (cagrilintide) with a GLP-1 agonist (semaglutide), each titrated toward 2.4 mg weekly. The two appetite mechanisms — amylin-mediated and GLP-1-mediated satiety — are additive, and the combination has advanced through Phase 3 (REDEFINE) as a fixed-dose product.
Russian Nootropic (Selank + Semax)
Selank and Semax are short peptides developed in Russia, where they are used clinically as nasal sprays. Selank is derived from tuftsin and associated with anxiolytic effects; Semax is an ACTH(4-10) fragment associated with focus and neuroprotection. Stacking them aims to pair calm (Selank) with drive/focus (Semax).
Tesamorelin + Ipamorelin
This pairing follows the classic GH-secretagogue logic of combining a GHRH analog with a ghrelin-receptor (GHRP) agonist, but upgrades the GHRH side to tesamorelin — a stabilized GHRH analog that is the only growth-hormone-axis peptide in this category with FDA-approved human efficacy data, specifically for reducing visceral adipose tissue in HIV-associated lipodystrophy (marketed as Egrifta). The premise is that tesamorelin amplifies the size of each GH pulse at the pituitary while ipamorelin, a highly selective ghrelin-receptor agonist, both adds a second, independent pulse trigger and suppresses somatostatin, the brake on GH release.
Cagrilintide + Tirzepatide
This combination layers three appetite mechanisms by pairing the long-acting amylin analog cagrilintide with the dual-incretin agonist tirzepatide (GIP + GLP-1). The logic directly mirrors CagriSema — which combines amylin with GLP-1 — but substitutes tirzepatide, whose added GIP activity already produces some of the largest weight-loss figures of any approved single molecule (up to roughly 21% in SURMOUNT-1). Stacking amylin-mediated satiety on top is intended to push appetite suppression further still.
Cagrilintide + Retatrutide
This is the most aggressive weight-loss combination on paper: it stacks the long-acting amylin analog cagrilintide on top of retatrutide, the triple-G agonist that activates the GIP, GLP-1, and glucagon receptors at once. Retatrutide alone produced the largest weight reductions reported for any pharmacological agent in its Phase 2 trial — about 24% at 48 weeks, with the curve still falling — and the glucagon component adds an energy-expenditure mechanism on top of the appetite suppression shared with other incretins. Adding amylin-mediated satiety layers a fourth, mechanistically distinct hunger signal onto that base.
Retatrutide + MOTS-c
This pairing combines a powerful appetite-and-expenditure agent with a metabolic-conditioning peptide. Retatrutide, the triple-G agonist (GIP/GLP-1/glucagon), drives the weight loss — appetite suppression plus glucagon-mediated energy expenditure. MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene that activates AMPK and is reported to improve insulin sensitivity, glucose handling, and metabolic flexibility, acting in skeletal muscle as a so-called 'exercise mimetic.'
Advanced Recomp (GH secretagogue + repair)
This is a body-recomposition construction that combines two goals in one protocol: amplifying the body's own growth-hormone output and supporting tissue recovery. The GH side uses the classic secretagogue pairing — CJC-1295 (no-DAC), a GHRH analog that increases the amount of GH released per pulse, plus ipamorelin, a selective ghrelin-receptor agonist that triggers a clean GH pulse without raising cortisol or prolactin. Acting on two different receptors, they amplify pulsatile GH and downstream IGF-1 more than either does alone.